A hematology drugmaker that could rise at least 60% and a gene therapy developer that could nearly double top the list of the favorite biotech stocks of a newly-hired analyst at Raymond James. Also making the list of top biotech stocks? A neurology stock, a hematology stock – and more. For a closer look at each of these biotech stocks,…
When it comes to the S&P 500 and one of the ETFs that represents the overall biotech sector (the iShares Nasdaq Biotechnology ETF), the author of today’s article observes that “the paths of these two investments appear to be diverging.” Given this apparent divergence, he questions whether, despite all the recent medical news, biotech stocks have already had their run.…
Both of the stocks highlighted in today’s article are clinical-stage biotechs, both are developing products to address the coronavirus pandemic (a vaccine in one case and a therapeutic in the other) – and both are “ultra-risky”. So what are the chances that either – or both – of these two ultra-risky stocks could make investors ultra wealthy? For more on…
One of the biotech stocks highlighted in today’s article is a well-established, large-cap name. The other is a far less established, small-cap player with no products currently on the market. What the two have in common, according to the author, is that both “have made significant breakthroughs — and could provide market-beating returns for many years to come as a…
Joining the ever-expanding list of COVID-19 stocks is this biotech that has filed an application with the FDA for initiation of Phase 2/Phase 3 clinical trials for its experimental monoclonal antibody therapy for the disease. The safety and tolerability of the therapy has already been demonstrated and, as today’s article explains, the company believes that its modulating effect “could reduce…
Of all the companies working on the development of potential COVID-19 vaccines and therapeutics, the one highlighted in today’s article – a small Israel-based biotech that specializes in blood plasma-based treatments – is one of the least well-known. However, given that plasma-based therapies have already been shown to be effective in treating severe cases of COVID-19, this company could start…
“As an investor, this sets up a great opportunity to get in on the ground floor and earn triple-digit profits in short order,” advises the author of today’s article in regards to a little-known segment of the thriving biotech industry that appears poised for a massive breakout to the upside in the coming months. Just what is this biotech segment…
Given the fact that it has already demonstrated remarkable performance without even having any products with regulatory approval for sale, just where could biotech CRISPR Therapeutics, with its focus on the treatment of serious diseases using its proprietary CRISPR/Cas9 gene-editing platform, be five years from now? For more on the promise of this firm’s pipeline projects, CLICK HERE.
While most of the attention in the biotech sector is focused on potential COVID-19 treatments or vaccines, the author of today’s article argues that there’s “a better way to play the sector, which is via companies whose roles in the daily grind of drug manufacturing and research will remain crucial regardless of the ups and downs of any particular acute…
In regards to the biotech sector, the author of today’s article advises that “it makes sense to keep an eye on this general area of the market as it is likely to play an increasingly significant role not just in the fight against Covid-19 but also in the war on cancer, the battle against rare diseases, and increasingly on more…